HIVbio: HIV Bioinformatics

G.P.S. Raghava | Department of Computational Biology | IMTECH | Developers | Contact
General Information
 Home HIVbio
HIV Genome
 HIV Proteome
 HIV Life Cycles
 HIV Imp Enzymes

Important Terms
 HIV Coreceptors
  HIV Tropism
  Structural Landmarks
  Important Databases

AIDS: Therapies
  Drugs : HAART
  Drug Resistance
 Therapeutics and Vaccines

 Bioinformatics Approach
  Coreceptor Predictions
 Slides (PPT/PDF)
 HIV Videos
 Research Centres/Journals

Drugs Against HIV

Antiretroviral drugs are medications for the treatment of infection by retroviruses, primarily HIV. When several such drugs, typically three or four, are taken in combination, the approach is known as highly active antiretroviral therapy, or HAART.
The drugs mainly includes :
* Reverse Transcriptase Inhibitor (NRTIs/NtRTIs , NNRTIs )
* Protease Inhibitors
* Fusion or Entry Inhibitors
* Integrase Inhibitors
NRTIs and NNRTIs are available in most countries. Fusion/entry inhibitors and integrase inhibitors are usually only available in resource-rich countries.
Protease inhibitors are generally less suitable for starting treatment in resource-limited settings due to the cost, number of pills which need to be taken, and the particular side effects caused by protease drugs.

There are currently more than 20 approved antiretroviral drugs in the US and Europe (including combined formulations) and many more in the expanded access programmes and trials.
Most antiretroviral drugs have at least three names. Sometimes a drug is referred to by its research or chemical name, such as AZT. The second name is the generic name for all drugs with the same chemical structure; for example AZT is also known as zidovudine. The third name is the brand name given by the pharmaceutical company; one of the brand names for zidovudine is Retrovir. Lastly, an abbreviation of the common name might sometimes also be used, such as ZDV, which is the fourth name given to zidovudine.
New development in HIV chemotherapy
New Retroviral Drugs
An Update in the Development of HIV Entry Inhibitors
Raltegravir and Etravirine Are Active against HIV Type 1 Group O
Strategies in design of Antiviral drugs
Tharapy Insight: body-shape changes and metabolic complications associated with HIV and HAART therapy